Non-small cell lung cancer · line 2 · Dabrafenib + trametinib (BRAF V600E+ NSCLC)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 2 |
|---|---|
| Track | standard |
| Linked regimen | REG-DABRAFENIB-TRAMETINIB-NSCLC |
| ID | IND-NSCLC-2L-BRAF-V600E-DAB-TRAM |
|---|---|
| Type | Indication |
| Status | reviewed 2026-04-27 | pending_clinical_signoff |
| Diseases | DIS-NSCLC |
| Sources | SRC-BRF113928-PLANCHARD-2016 SRC-ESMO-NSCLC-METASTATIC-2024 SRC-NCCN-NSCLC-2025 |
Notes
STUB — pending Clinical Co-Lead sign-off. Standard-track for BRAF V600E+ NSCLC any line. Encorafenib + binimetinib (PHAROS) is alternative — separate future Indication.
Used By
Algorithms
ALGO-NSCLC-METASTATIC-2L- ALGO-NSCLC-METASTATIC-2L
Indication
IND-NSCLC-BRAF-V600E-1L-DAB-TRAM- IND-NSCLC-BRAF-V600E-1L-DAB-TRAM